Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women

Sherene S. Min, Amanda H. Corbett, Naser Rezk, Susan Cu-Uvin, Susan A. Fiscus, Leslie Petch, Myron S. Cohen, Angela D.M. Kashuba

Research output: Contribution to journalArticle

45 Scopus citations

Abstract

The pharmacokinetics of antiretrovirals (ARVs) in the female genital tract (FGT) are likely to influence vertical and sexual transmission of HIV, the development of viral resistance, and post-exposure prophylaxis regimens. This study is the first to compare ARV concentrations in direct aspirates of cervicovaginal fluid (CVF) and blood plasma (BP). This unique method provides direct assessment of concentrations without the confounding of cervicovaginal lavage dilution. Of 8 ARVs, CVF concentrations ranged from <10% to >100% of BP concentrations. These large differences in CVF penetration suggest that further research into ARV pharmacokinetics and drug efficacy in the FGT is necessary.

Original languageEnglish (US)
Pages (from-to)1577-1580
Number of pages4
JournalJournal of Acquired Immune Deficiency Syndromes
Volume37
Issue number5
DOIs
StatePublished - Dec 15 2004

Keywords

  • Antiretroviral concentration
  • Female genital tract
  • HIV-1
  • Nonnucleoside reverse transcriptase inhibitor
  • Pharmacokinetic
  • Protease inhibitor

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women'. Together they form a unique fingerprint.

Cite this